Literature DB >> 24554605

Targeting low-density lipoprotein and dysmetabolism in type 2 diabetes mellitus.

Ronald Goldberg1.   

Abstract

Entities:  

Keywords:  Editorials; LDL-cholesterol; type 2 diabetes

Mesh：

Substances：

Year:  2014        PMID： 24554605      PMCID： PMC4067598          DOI： 10.1161/ATVBAHA.114.303171

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  11 in total

1.  Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells.

Authors:  Yoshiyuki Hattori; Kunihiro Suzuki; Sachiko Hattori; Kikuo Kasai
Journal:  Hypertension       Date:  2006-04-24       Impact factor: 10.190

2.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

3.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Authors:  Paul M Ridker; Aruna Pradhan; Jean G MacFadyen; Peter Libby; Robert J Glynn
Journal:  Lancet       Date:  2012-08-11       Impact factor: 79.321

4.  ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK.

Authors:  Sergey Filippov; Stephen L Pinkosky; Richard J Lister; Catherine Pawloski; Jeffrey C Hanselman; Clay T Cramer; Rai Ajit K Srivastava; Timothy R Hurley; Cheryl D Bradshaw; Mark A Spahr; Roger S Newton
Journal:  J Lipid Res       Date:  2013-05-24       Impact factor: 5.922

5.  Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.

Authors:  Christie M Ballantyne; Michael H Davidson; Diane E Macdougall; Harold E Bays; Lorenzo A Dicarlo; Noah L Rosenberg; Janice Margulies; Roger S Newton
Journal:  J Am Coll Cardiol       Date:  2013-06-13       Impact factor: 24.094

6.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.

Authors:  William C Knowler; Sarah E Fowler; Richard F Hamman; Costas A Christophi; Heather J Hoffman; Anne T Brenneman; Janet O Brown-Friday; Ronald Goldberg; Elizabeth Venditti; David M Nathan
Journal:  Lancet       Date:  2009-10-29       Impact factor: 79.321

7.  AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism.

Authors:  Stephen L Pinkosky; Sergey Filippov; Rai Ajit K Srivastava; Jeffrey C Hanselman; Cheryl D Bradshaw; Timothy R Hurley; Clay T Cramer; Mark A Spahr; Ashley F Brant; Jacob L Houghton; Chris Baker; Mark Naples; Khosrow Adeli; Roger S Newton
Journal:  J Lipid Res       Date:  2012-11-01       Impact factor: 5.922

8.  Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.

Authors:  D K Coletta; A Sriwijitkamol; E Wajcberg; P Tantiwong; M Li; M Prentki; M Madiraju; C P Jenkinson; E Cersosimo; N Musi; R A Defronzo
Journal:  Diabetologia       Date:  2009-01-24       Impact factor: 10.122

9.  AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function.

Authors:  Laura L Dugan; Young-Hyun You; Sameh S Ali; Maggie Diamond-Stanic; Satoshi Miyamoto; Anne-Emilie DeCleves; Aleksander Andreyev; Tammy Quach; San Ly; Grigory Shekhtman; William Nguyen; Andre Chepetan; Thuy P Le; Lin Wang; Ming Xu; Kacie P Paik; Agnes Fogo; Benoit Viollet; Anne Murphy; Frank Brosius; Robert K Naviaux; Kumar Sharma
Journal:  J Clin Invest       Date:  2013-10-25       Impact factor: 14.808

10.  Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.

Authors:  R Goldberg; M Temprosa; J Otvos; J Brunzell; S Marcovina; K Mather; R Arakaki; K Watson; E Horton; E Barrett-Connor
Journal:  J Clin Endocrinol Metab       Date:  2013-08-26       Impact factor: 5.958
View more
  1 in total

Review 1.  Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future.

Authors:  Evan A Stein; Frederick J Raal
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.